ADVM News and Press, Adverum Biotechnologies Inc. From 03/21/24

A look at the top 10 most actives in the United States Yield10 Bioscience Inc. (YTEN) rose 135.5% to $0.5722 on volume of 57,300,938 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 8.7% to $3.16 on volume of 30,926,102 shares Kaival Brands Innovations Group Inc. (KAVL) rose...

2024-03-20 09:02:02 ET Adverum Biotechnologies Inc (ADVM) announced stock split at a ratio of 1-for-10 on 2024-03-21 ... Full story available on KlickAnalytics.com

2024-03-19 16:04:27 ET Summary Ocular Therapeutics' stock has surged 184% in six months, driven by promising clinical assets in eye disease treatments. Dextenza's success illustrates Ocular's Elutyx technology potential, but Paxtrava faces tough competition and logistical challeng...

2024-03-19 10:00:51 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...

2024-03-18 16:35:03 ET More on Adverum Biotechnologies Seeking Alpha’s Quant Rating on Adverum Biotechnologies Historical earnings data for Adverum Biotechnologies Financial information for Adverum Biotechnologies Read the full article on Seeking Alp...

- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed $127.5 million private placement financing with new and existing institutional investors...

REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executi...

2024-02-22 06:15:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Despite a recent decline in the leading economic index, the U.S. economy is positioned for a positive future in 2024. Strong employment and robust stock levels contribute to the optimistic outl...

2024-02-19 20:42:02 ET Summary Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness, with wet AMD being a more severe form. Current treatment for wet AMD involves frequent anti-VEGF injections, but there is a need for therapies with less frequent ...

REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief execut...